Published in Clin Infect Dis on May 01, 2008
Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics (2009) 3.32
Pneumococcal serotypes causing pediatric meningitis in Turkey: application of a new technology in the investigation of cases negative by conventional culture. Eur J Clin Microbiol Infect Dis (2010) 0.90
Update on the success of the pneumococcal conjugate vaccine. Paediatr Child Health (2011) 0.90
Prevnar 7 Childhood Immunization Program and Serotype Replacement: Changes in Pneumococcal Incidence and Resulting Impact on Health Care Costs in Alberta (2003-2008). Drugs Real World Outcomes (2015) 0.75
Pneumococcal necrotizing pneumonia in Utah: does serotype matter? Clin Infect Dis (2008) 2.72
Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics (2005) 3.42
Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics (2009) 3.32
Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis (2008) 2.70
Population genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet (2013) 2.63
Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J Infect Dis (2009) 2.36
HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol (2005) 2.24
Nontypeable Haemophilus influenzae as a pathogen in children. Pediatr Infect Dis J (2009) 2.12
Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis (2006) 1.99
Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2012) 1.98
Host-derived sialic acid is incorporated into Haemophilus influenzae lipopolysaccharide and is a major virulence factor in experimental otitis media. Proc Natl Acad Sci U S A (2003) 1.75
Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics (2010) 1.72
Otitis media and its consequences: beyond the earache. Lancet Infect Dis (2010) 1.68
Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr Infect Dis J (2010) 1.67
Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J (2012) 1.41
Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq. Vaccine (2009) 1.40
Severity of invasive pneumococcal disease in children caused by susceptible and nonsusceptible isolates. Pediatr Infect Dis J (2014) 1.40
Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children. Pediatrics (2005) 1.39
Antibiotic-resistant Streptococcus pneumoniae in the heptavalent pneumococcal conjugate vaccine era: predictors of carriage in a multicommunity sample. Pediatrics (2003) 1.37
Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J (2006) 1.32
Carried pneumococci in Massachusetts children: the contribution of clonal expansion and serotype switching. Pediatr Infect Dis J (2011) 1.28
Role of complement in defense of the middle ear revealed by restoring the virulence of nontypeable Haemophilus influenzae siaB mutants. Infect Immun (2006) 1.25
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine (2010) 1.23
Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens. Proc Natl Acad Sci U S A (2013) 1.23
Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J (2002) 1.22
A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. Vaccine (2010) 1.22
Experimental acute otitis media due to nontypeable Haemophilus influenzae: comparison of high and low azithromycin doses with placebo. Antimicrob Agents Chemother (2002) 1.20
Hepatocyte-specific mutation of both NF-κB RelA and STAT3 abrogates the acute phase response in mice. J Clin Invest (2012) 1.16
The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine (2011) 1.14
Re-emergence of the type 1 pilus among Streptococcus pneumoniae isolates in Massachusetts, USA. Vaccine (2010) 1.12
Epidemiology and risk factors for Staphylococcus aureus colonization in children in the post-PCV7 era. BMC Infect Dis (2009) 1.11
Using pneumococcal carriage data to monitor postvaccination changes in invasive disease. Am J Epidemiol (2013) 1.09
Role of complement in host defense against pneumococcal otitis media. Infect Immun (2009) 1.09
Evolving picture of invasive pneumococcal disease in massachusetts children: a comparison of disease in 2007-2009 with earlier periods. Pediatr Infect Dis J (2012) 1.08
Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts' children. Pediatr Infect Dis J (2014) 1.05
Differential occurrence of Streptococcus pneumoniae serotype 11E between asymptomatic carriage and invasive pneumococcal disease isolates reflects a unique model of pathogen microevolution. Clin Infect Dis (2012) 1.01
Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Vaccine (2009) 1.00
Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Pediatrics (2007) 1.00
Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2009) 0.97
Multiple consecutive lavage samplings reveal greater burden of disease and provide direct access to the nontypeable Haemophilus influenzae biofilm in experimental otitis media. Infect Immun (2007) 0.95
Underlying conditions in children with invasive pneumococcal disease in the conjugate vaccine era. Pediatr Infect Dis J (2011) 0.94
Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine (2005) 0.93
Sialic acid mediated transcriptional modulation of a highly conserved sialometabolism gene cluster in Haemophilus influenzae and its effect on virulence. BMC Microbiol (2010) 0.90
Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy. Vaccine (2013) 0.89
Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors. Antimicrob Agents Chemother (2008) 0.89
Prevention of invasive pneumococcal disease in HIV-infected children: expanding the toolbox. J Infect Dis (2009) 0.89
Recent advances in otitis media. 6. Vaccine. Ann Otol Rhinol Laryngol Suppl (2005) 0.88
Streptococcus pneumoniae clonal complex 199: genetic diversity and tissue-specific virulence. PLoS One (2011) 0.87
Prevalence and genetic diversity of nontypeable haemophilus influenzae in the respiratory tract of infants and primary caregivers. Pediatr Infect Dis J (2012) 0.86
Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection. J Immunol (2003) 0.85
A second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in children. Curr Opin Pediatr (2011) 0.82
Virulence of Streptococcus pneumoniae serotype 6C in experimental otitis media. Microbes Infect (2012) 0.81
Formulations for trans-tympanic antibiotic delivery. Biomaterials (2012) 0.81
Heptavalent pneumococcal conjugate vaccine: current and future impact. Expert Rev Vaccines (2003) 0.80
Capacity of serotype 19A and 15B/C Streptococcus pneumoniae isolates for experimental otitis media: Implications for the conjugate vaccine. Vaccine (2010) 0.80
Detection of group B streptococcal bacteremia in simulated intrapartum antimicrobial prophylaxis. Diagn Microbiol Infect Dis (2003) 0.77
Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly. PLoS One (2013) 0.77
Conjugate meningococcal vaccines: lifesaving or inefficient use or both-no easy answer. Clin Infect Dis (2010) 0.76
Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338). AIDS Res Ther (2007) 0.75
Seasonal variation in penicillin susceptibility and invasive pneumococcal disease. Pediatr Infect Dis J (2015) 0.75
Pediatric respiratory tract infections: etiology, microbiology and resistance trends. Introduction. Pediatr Infect Dis J (2003) 0.75
Clinically based surveillance of invasive meningococcal disease in young children admitted to selected US hospitals between January 2000 and June 2009: a retrospective cohort study. Hum Vaccin Immunother (2012) 0.75
Increasing focus on local epidemiology demonstrates potential value of pneumococcal conjugate vaccines in Middle East and North Africa Region. Vaccine (2012) 0.75
Xanthomas and hyperlipidemia in a human immunodeficiency virus-infected child receivng highly active antiretroviral therapy. Pediatr Infect Dis J (2002) 0.75